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Our understanding of quality in pharmaceutical production
has evolved significantly over the past decade. The quality-by-
design initiative has proved to be a catalyst for those working
in the pharmaceutical science community to reconsider
established quality testing protocols and focus research on
the effect of processing steps on the quality of dosage forms.
With clear progress being made in the implementation of
continuous processing into industrial practice there has also
been a realisation that pharmaceutical engineering and mate-
rials sciences need to be better integrated into existing prac-
tice. Traditionally, the pharmaceutical development process,
the regulatory process and the testing requirements outlined
in the pharmacopeias place a strong emphasis on chemical
purity and drug content as well as the safety and efficacy of
the medicines. It is this context that has dominated the per-
ception of quality in our community and with which we are all
familiar. However, it has become increasingly clear that in
order to achieve stable manufacturing processes that result
in consistent product quality it is now critical to understand
the physical characteristics of drug products in far greater
detail than is currently the status quo. The microstructure, that
is the physical structure at microscopic scale, determines a
significant range of critical quality attributes of a dosage form,
given their nature as complex multi-particulate mixtures of
drug and excipients. Thus there is a continuing need for better
fundamental understanding of the interdependence of micro-
structure and product quality. The lack of sufficiently sensitive
measurement techniques and the limited awareness of the role
of microstructure for pharmaceutical quality present signifi-
cant barriers that restrict the production of drug products of
the highest quality and within sustainable and economic pro-
cesses. It is this lacuna that the current themed issue aims to
address, through raising awareness, educating and highlight-
ing recent developments that the editors believe have the po-
tential for having a significant impact on the field.
In contrast to the chemical structure of the drug and excip-
ients, the microstructure of the dosage form is defined during
the manufacturing process. The same chemical can exhibit a
wide range of performance characteristics depending on its
physical structure, much like crystalline polymorphs, from a
chemical point of view, are identical but will have different
solubilities. The role of the microstructure is well illustrated by
the example of dissolution testing of immediate release tablets
that contain a BCS class I drug. The compendial tests typically
require a high fraction of the drug, e.g. 75 or 80%, to be
released and dissolved from the dosage form in time periods
of 30–45 min. However, closer inspection of the drug release
profiles shows that in the vast majority of cases the drug release
characteristics vary enormously in the early stages of the test
(e.g. at times <15 min) and the variability of the drug concen-
tration only gradually decreases to the ‘acceptable’ threshold
close to the defined testing point as specified in the respective
compendial method. This variation in release characteristics is
directly linked to the disintegration process, which itself is
determined by the dosage form microstructure. The review
by D. Markl and J.A. Zeitler outlines the fundamental origins
of this link and how a lack of meaningful testing protocols has
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resulted in a lack of appreciation of the connection between
physical structure and the quality of the dosage form.
C.C. Sun further develops the argument by highlighting
how microstructure not only determines the disintegration of
the dosage form but also its mechanical properties that can be
achieved by powder compaction. This is of critical importance
both in terms of designing the optimal particle characteristics
during formulation development and selecting the most ap-
propriate processing route and conditions. The interplay be-
tween process parameters, the microstructure and the
resulting product performance are critical for defining and
evolving the design space during process development and
scale up. Even though the formulation is the same, the
resulting dosage form can behave very differently. In other
words, the microstructure is the key characteristic to under-
stand prior to rational design.
The review by Y. Sun and J. Østergaard complements this
discussion by highlighting opportunities that can be realised
by replacing traditional UV spectroscopy with modern UV
imaging methods for the analysis of the dissolution process.
This methodology makes it possible to understand better the
interaction between drug and excipients within the formula-
tion and how this can result in different structures (for example
in gels, which strongly affect the drug release characteristics of
the dosage form). The study by A. Hu et al. highlights this
thesis further by providing more in-depth insights into the
physicochemical changes that take place within the dosage
form during dissolution from a matrix system. Using quanti-
tative magnetic resonance imaging (MRI) experiments and
confocal microscopy it is possible to rationalise the structural
changes in hydrophilic polymer matrices during drug release.
It also sheds light on our understanding of how structural
changes affect the mass transport of dissolution liquid into
the gel structure and drug out of the dosage form.
An attractive and increasingly popular practice in solid
state formulation development is using amorphous drug to
increase the bioavailability of poorly soluble drug compounds.
But, given that amorphous drug substances are inherently
metastable and will eventually convert into a less soluble crys-
talline form, it is of critical importance to be able to detect
crystalline material with sufficient sensitivity and to under-
stand what triggers the crystallisation process. At present, a
typical quality control method will attempt to measure the
total crystallinity of the entire sample. This is problematic
for a number of reasons. Besides the fact that most measure-
ments do not sample the entire volume of a dosage form there
is no technique that can reliably detect trace amounts of crys-
talline material in a bulk sample with sufficient sensitivity.
However, even a trace of crystalline material that is spatially
confined to a small area of the dosage form can act as a
nucleation site from which crystallisation can take place rap-
idly and throughout the dosage form. The contribution by
P.T. Mah et al. provides a fascinating insight into the spatial
distribution of crystallinity induced by compression of an
amorphous drug substance. The authors were able to demon-
strate that, while the presence of excipients did affect the rate
of surface crystallisation, it was not able to prevent
crystallisation upon tableting. It is important to highlight here
that a physical mixture of drug/excipient was used for this
study rather than a solid dispersion. The measurements were
preformed using a combination of well-established physical
surface characterisation techniques such as scanning electron
microscopy and attenuated total reflection (ATR) infrared
spectroscopy as well as sum frequency generation microscopy
(a highly sensitive optical measurement technique that can
reliably detect crystallinity of non-centrosymmetric samples).
M. Alhijjaj et al. use the example of an amorphous
solid dispersion prepared using a hot melt extrusion pro-
cess to study the stability of the amorphous drug within
the polymer matrix. This combination of formulation
and process is one of the preferred industrial platforms
for realising amorphous dosage forms. By using advanced
thermal analysis rout ines combined with X-ray
microtomography the authors were able to confirm that
the crystallisation process is preceded by a phase separa-
tion process and the crystal nuclei clearly form from
within in the drug domains. The combination of thermal
characterisation and spatial resolution of the process pro-
vides a unique insight into how the physical structure
presets the conditions for the crystallisation process.
Following the theme of amorphous stabil ity, K.
Punčochová et al. further emphasise how different imag-
ing techniques based on vibrational spectroscopy, as well
as MRI, can be used to analyse the drug release process
from a solid dispersion formulation. Even if the formula-
tion is stable and the drug molecules are successfully kept
in their amorphous state, the solubility advantage can be
lost during the drug release process in the patient’s
gastro-intestinal tract. This complex process includes
mass transport of dissolution liquid into the matrix,
swelling, dissolution and supersaturation as well as mass
transport out of the drug/polymer matrix. The authors
show how it is possible to detect the onset of unwanted
crystallisation using the imaging approach during formu-
lation development and how this information can be
used to develop a systematic strategy for it.
The next two contributions turn the focus of this theme
issue from the formulation and its microstructure at the
molecular and domain level to the next larger length scale:
the inter-particle scale in granular materials and its effect
on tablet structure following compaction. S. van den Ban
and D.J. Goodwin describe the development of a high
shear wet granulation process to achieve granules with a
wide range of densities. This work is a prime example of a
quality-by-design driven process development and how this
can be realised at production scale. Clearly the density of
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the granules is of critical importance and largely accords to
the microstructure in the subsequent compaction process.
Using the tablets produced from these granules as an ex-
ample, D. Markl et al. show how the bulk porosity of a
tablet can be measured non-destructively and without
any prior sample preparation using terahertz spectroscopy.
The authors argue that porosity is a key critical quality
attribute for immediate release tablets, and one that is far
better suited to predict disintegration of dissolution char-
acteristics than, for example, tablet hardness.
In the final two articles, attention shifts away from tradi-
tional solid dosage forms to emerging drug delivery technolo-
gies based on 3D printing.M. Edinger et al. introduce a proof-
of-concept study of how Raman spectroscopy and imaging
methods can be used in inkjet-printed drug delivery systems
to resolve the drug distribution within the dosage form.
Finally, with the example of a set of 3D printed dosage forms
prepared using the fused deposition modelling technique, D.
Markl et al. demonstrate the significant discrepancy in inter-
nal structure between the computer aided design models and
the actual structures that can be realised using such technolo-
gy. Whilst there is considerable enthusiasm in the pharmaceu-
tical community to take advantage of the exciting opportuni-
ties in 3D printing a meaningful discussion regarding the
unique requirements to define dosage form quality is yet to
take place and, as demonstrated by this work, microstructure
will have to be a central concern.
That new dosage forms and processing techniques require
new analytical technologies as meaningful descriptors of qual-
ity is a key message expressed by all contributors to this issue.
The tools currently described or required by the
pharmacopoeiae are no longer fit for purpose as, typically,
they do not allow us to quantify the role or effect of the mi-
crostructure for the performance of the formulation or dosage
form. There needs to be a shared motivation in pharmaceu-
tical development and engineering to develop the tools that
the pharmaceutical industry need in order to meet two key
challenges of our time: improved drug product quality and a
shift to continuous manufacturing. The ability to rationally
design, reproduce and reliably detect a well-defined micro-
structure will be essential to these endeavours, not least to
implement meaningful process analytical technologies and
control strategies into the manufacturing process.
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